![]() |
The ONS PodcastAuthor: Oncology Nursing Society
Where ONS Voices Talk Cancer Join oncology nurses on the Oncology Nursing Society's award-winning podcast as they sit down to discuss the topics important to nursing practice and treating patients with cancer. ISSN 2998-2308 Language: en Genres: Education, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Episode 442: Hodgkin Lymphoma Treatment Considerations for Oncology Nurses
Episode 442
Friday, 20 November, 2026
"With such a high cure rate, the goal of clinical trials has really become tailoring treatment to provide enough therapy that we achieve remission without creating this unnecessary toxicity. We're also are doing more risk-adapted therapy, so if you can identify features that are low- versus high-risk, stratify patients into those groups, tailor their therapy based on what you anticipate their risk to be, and then assess their response to therapy, that can really make a difference in the kind of therapy that they're receiving," ONS member Elizabeth Cummings, MSN, CPNP-AC, CPHON®, radiation oncology nurse practitioner at Children's Hospital of Philadelphia in Pennsylvania told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about Hodgkin lymphoma treatment considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 10 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by November 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of Hodgkin lymphoma. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 435: An Overview of Hodgkin Lymphoma for Oncology Nurses Episode 365: Radiation-Associated Secondary Cancers Episode 208: How to Have Fertility Preservation Conversations With Your Patients ONS Voice articles: Fertility Preservation Protects Possibilities for Patients With Cancer Have Meaningful Conversations With Pediatric, Adolescent, and Young Adult Patients and Their Families Non-Hodgkin Lymphoma Symptoms, Diagnosis, Treatment, and Survivorship Recommendations Oncology Nursing Forum article: Symptom Clusters in Lymphoma Survivors Before, During, and After Chemotherapy: A Prospective Study ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) Joint position statement from the Association of Pediatric Hematology/Oncology Nurses, Canadian Association of Nurses in Oncology/Association Canadienne des Infirmières en Oncologie, and ONS: Fertility Preservation in Individuals With Cancer ONS huddle cards: Fertility Preservation Late Effects of Cancer Treatment Huddle Card Radiation American Society of Clinical Oncology (ASCO) poster session: Modern Hodgkin Lymphoma Treatments to Reduce Second Cancer Risks: Influence of Risk-Adapted Screening Children's Oncology Group: Hodgkin Lymphoma Journal of the National Comprehensive Cancer Network (NCCN) article: Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines in Oncology UpToDate: Hodgkin Lymphoma Treatment To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Hodgkin lymphoma is highly curable. ... Hodgkin lymphoma is interesting in that it has a bimodal age distribution. You'll see it in this adolescent and young adult (AYA) population but then also in older adult populations. Initially, treatments were found to be pretty toxic to this younger, sometimes still-growing, AYA population who have this much longer anticipated lifespan. And so over time, we quickly found a divergence in these treatment paradigms. The Children's Oncology Group developed more of these pediatric and AYA protocols and their focus was on decreasing late effects, whereas adult cooperative groups really started to develop their own protocols, and their primary outcome was cure. So these paradigms developed independently but also in parallel, which interestingly means that a young adult patient could receive different therapy depending on which type of hospital provides their treatment." TS 2:00 "Intensity-modulated radiation therapy or pencil beam-scanning protons are both the techniques and the tools that we can use to minimize the amount of dose that's going to the healthy tissues. … Back in the 1950s, they were using that anterior-posterior, posterior-anterior (AP-PA) and everything in the field was getting the same dose. With this, we're able to really sculpt the dose and the healthy tissues are seeing a lot less radiation exposure. As a result, there has been a dramatic reduction in both the dose and the volume of healthy tissue that receives radiation. And so for survivorship, they were able notice that the risk of these serious late effects declined significantly. It takes a long time to be able to assess the late effects of a treatment, but when they looked at survivors in the 1970s compared to survivors in the 1990s, they could see a pretty dramatic reduction in those late effects." TS 12:36 "Adolescent and young adulthood can be such a challenging time in and of itself. And then we're adding a cancer diagnosis to this. It's a time of life where there's typically kind of increasing independence. They're building relationships. They're figuring out their career trajectory. They're trying to develop autonomy and become more independent. And a cancer diagnosis really can stall that. While physically, this population is able to tolerate more intensive therapy ... they really are going to be in a different place than a lot of their peers in terms of dealing with this diagnosis mentally and psychosocially. It's a real difference. This population may be more vulnerable to body image issues, hair loss, fluctuations in weight, and a lot of times they're on steroids. Ensuring they have access to resources and psychosocial support is super helpful." TS 17:43 "Nurses are at the bedside. They're the ones who are building relationships. A lot of times they are much closer in age to the patients than physicians and providers, which can often give them a unique opportunity. I have found that just by virtue of proximity and the amount of time that as a nurse, you're spending in a patient's room, that they are often privy to a little more information than maybe a patient is willing to share with somebody else. And that's a really unique role. Being able to capitalize on that, they may be more open to talking about things like their sexual health or fertility." TS 21:29 "I think it's interesting that in this population, secondary malignancies are the leading cause of death among survivors. Cardiovascular disease is a leading noncancer cause. We really have to educate our patients about the importance of all of these screenings. Survivorship surveillance is lifelong. We discussed it's great that treatment is done, but it doesn't mean that they can kind of forget about this and just move on and not think about it ever again. This is something that's going to be part of their life forever." TS 27:20













